Insmed Incorporated is a NASDAQ-listed (INSM) global biopharmaceutical company developing and commercializing therapies for people with serious and rare diseases. Its approved medicines include ARIKAYCE (amikacin liposome inhalation suspension) for refractory Mycobacterium avium complex lung disease and BRINSUPRI (brensocatib) for bronchiectasis. - View it on GitHub